{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:09:03Z","timestamp":1787724543017,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ctro.2022.04.011","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T12:19:47Z","timestamp":1652444387000},"page":"64-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Second malignancies in patients with Hodgkin\u2019s Lymphoma: Half a century of experience"],"prefix":"10.1016","volume":"35","author":[{"given":"Bouthaina","family":"Shbib Dabaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boyce-Fappiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Damron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Gunther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Abou Yehia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferial","family":"Shihadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Pinnix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea K.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.ctro.2022.04.011_b0005","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ctro.2022.04.011_b0010","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","article-title":"Second malignant neoplasms among long-term survivors of Hodgkin\u2019s disease: a population-based evaluation over 25 years","volume":"20","author":"Dores","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2022.04.011_b0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jnci\/85.1.25","article-title":"Breast cancer after treatment of hodgkin\u2019s disease","volume":"85","author":"Hancock","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.ctro.2022.04.011_b0020","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2022.04.011_b0025","article-title":"Rapidly alternating COPP\/ABV\/IMEP is not superior to conventional alternating COPP\/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin\u2019s lymphoma: Final results of the German Hodgkin\u2019s Lymphoma Study Group trial HD5","volume":"20","author":"Sieber","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2022.04.011_b0030","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"issue":"7","key":"10.1016\/j.ctro.2022.04.011_b0035","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced Treatment Intensity in Patients with Early-Stage Hodgkin\u2019s Lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.ctro.2022.04.011_b0040","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the german hodgkin study group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ctro.2022.04.011_b0045","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin\u2019s lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctro.2022.04.011_b0050","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ctro.2022.04.011_b0055","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctro.2022.04.011_b0060","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.3390\/ijerph9072444","article-title":"Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor","volume":"9","author":"Ezoe","year":"2012","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"10.1016\/j.ctro.2022.04.011_b0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3857\/roj.2018.00290","article-title":"Radiation induced secondary malignancies: a review article","volume":"36","author":"Dracham","year":"2018","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.ctro.2022.04.011_b0070","series-title":"Statistics in PracticeCompeting Risks","year":"2006"},{"issue":"3","key":"10.1016\/j.ctro.2022.04.011_b0075","doi-asserted-by":"crossref","DOI":"10.1214\/aos\/1176350951","article-title":"A class of $K$-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"446","key":"10.1016\/j.ctro.2022.04.011_b0080","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"11","key":"10.1016\/j.ctro.2022.04.011_b0085","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1002\/cncr.23081","article-title":"Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma","volume":"110","author":"Hodgson","year":"2007","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.ctro.2022.04.011_b0090","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctro.2022.04.011_b0095","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.ctro.2022.04.011_b0100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2000.18.3.487","article-title":"Long-term risk of second malignancy in survivors of Hodgkin\u2019s disease treated during adolescence or young adulthood","volume":"18","author":"van Leeuwen","year":"2000","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ctro.2022.04.011_b0105","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/jnci\/dji290","article-title":"Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma","volume":"97","author":"Travis","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"27","key":"10.1016\/j.ctro.2022.04.011_b0110","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO.2013.50.6832","article-title":"stomach cancer risk after treatment for Hodgkin lymphoma","volume":"31","author":"Morton","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctro.2022.04.011_b0115","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/annonc\/mdu287","article-title":"Pancreatic cancer risk after treatment of Hodgkin lymphoma","volume":"25","author":"Dores","year":"2014","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ctro.2022.04.011_b0120","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3109\/10428194.2013.871631","article-title":"Radiation therapy for early stage unfavorable Hodgkin lymphoma: is dose reduction feasible?","volume":"55","author":"Laskar","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.ctro.2022.04.011_b0125","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clml.2017.12.007","article-title":"Consolidation radiation therapy for patients with advanced Hodgkin lymphoma in complete metabolic response according to PET-CT or gallium imaging","volume":"18","author":"Song","year":"2018","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"issue":"31","key":"10.1016\/j.ctro.2022.04.011_b0130","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctro.2022.04.011_b0135","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ctro.2022.04.011_b0140","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"223","key":"10.1016\/j.ctro.2022.04.011_b0145","article-title":"Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma (GHSGHD17): a multicentre open-label, randomized, Phase 3 trial","volume":"2","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2022.04.011_b0150","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2022.04.011_b0155","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: an overview of international lymphoma radiation oncology group guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2022.04.011_b0160","doi-asserted-by":"crossref","DOI":"10.1186\/1748-717X-7-186","article-title":"Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin\u2019s lymphoma: dosimetric comparison and clinical considerations","volume":"7","author":"Fiandra","year":"2012","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2022.04.011_b0165","doi-asserted-by":"crossref","DOI":"10.1186\/1748-717X-9-94","article-title":"Dosimetric advantages of a \u201c butterfly\u201d technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin\u2019s lymphoma","volume":"9","author":"Voong","year":"2014","journal-title":"Radiat Oncol"},{"issue":"16","key":"10.1016\/j.ctro.2022.04.011_b0170","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the international lymphoma radiation oncology group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctro.2022.04.011_b0175","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijrobp.2019.02.001","article-title":"The optimal use of imaging in radiation therapy for lymphoma: guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"104","author":"Mikhaeel","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ctro.2022.04.011_b0180","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin\u2019s lymphoma","volume":"82","author":"Paumier","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2022.04.011_b0185","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/0284186X.2014.932435","article-title":"Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: Benefit of deep inspiration breath-hold","volume":"54","author":"Petersen","year":"2015","journal-title":"Acta Oncol (Madr)"},{"issue":"1","key":"10.1016\/j.ctro.2022.04.011_b0190","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2015.01.013","article-title":"Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?","volume":"92","author":"Aznar","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ctro.2022.04.011_b0195","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.radonc.2018.08.017","article-title":"Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma","volume":"129","author":"Starke","year":"2018","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2022.04.011_b0200","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ijrobp.2009.11.013","article-title":"Radiation for Hodgkin\u2019s lymphoma in young female patients: a new technique to avoid the breasts and decrease the dose to the heart","volume":"79","author":"Dabaja","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:08:58Z","timestamp":1762502938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630822000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":40,"alternative-id":["S2405630822000349"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2022.04.011","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second malignancies in patients with Hodgkin\u2019s Lymphoma: Half a century of experience","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2022.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}